Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticolubant SCHEMBL1892766 | 1.00 | LTB4R (1.00) | LTB4R | |
| Ticolubant SCHEMBL1230392 | 1.00 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7020052 | 0.95 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7020057 | 0.95 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7016952 | 0.94 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7020389 | 0.94 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7021487 | 0.94 | LTB4R (0.94) | LTB4R | |
| SCHEMBL7021492 | 0.94 | LTB4R (0.94) | LTB4R | |
| SCHEMBL7020038 | 0.93 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7020046 | 0.93 | LTB4R (1.00) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250236674-A9 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250236594-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2025-07-24 | — | — | US | disclosed |
| CN-119954759-A | Benzopyran COX-2 inhibitor and application thereof | 安炎达医药技术(广州)有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250127793-A1 | CONJUGATES OF SURROGATE LIGHT CHAIN CONSTRUCTS | REVOPSIS HOLDINGS, LLC | 2025-04-24 | — | — | US | disclosed |
| US-12269801-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250090676-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | SUTRO BIOPHARMA, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12252552-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250002595-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX INC (US) | 2025-01-02 | — | — | US | disclosed |
| CN-111499684-B | Anti-CD 70 antibody drug conjugates | AMBRX公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-109069664-B | anti-CD 74 antibody conjugates, compositions comprising anti-CD 74 antibody conjugates, and methods of use of anti-CD 74 antibody conjugates | 苏特罗生物制药公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220143209-A1 | BETA-GLUCURONIDE-LINKER DRUG CONJUGATES | SEAGEN INC (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220089759-A1 | USE OF ANTI-CD40 ANTIBODIES FOR TREATMENT OF INFLAMMATORY CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-03-24 | — | — | US | disclosed |
| WO-2022061061-A1 | USE OF ANTI-CD40 ANTIBODIES FOR TREATMENT OF INFLAMMATORY CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-03-24 | — | — | WO | disclosed |
| EP-3962951-A1 | ANTI-BCMA ANTIBODY CONJUGATES | Sutro Biopharma, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220047716-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3584255-B1 | MODIFIED AMINO ACIDS COMPRISING AN AZIDO GROUP | SUTRO BIOPHARMA INC (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-2099823-B2 | VARIANT TARGET BINDING AGENTS AND USES THEREOF | SEAGEN INC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11242394-B2 | Anti-CD40 antibodies | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-08 | — | — | US | disclosed |
| EP-2609932-B1 | VARIANT TARGET BINDING AGENTS AND USES THEREOF | SEAGEN INC (US) | 2022-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252552-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | FCGR2A, FCGR3B, FCGR1A | LTB4R 2559/4885 |
| US-20250090676-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | FOLR1, FOLR2, DHFR | LTB4R 1331/4885 |
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | FCGR2A, FCGR3B, FCGR1A | LTB4R 2559/4885 |
| US-12269801-B2 | Modified amino acids | PTMS, DNPEP, ANPEP | LTB4R 2470/4885 |
| US-20220047716-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | LTB4R 1090/4885 |
| US-20220143209-A1 | BETA-GLUCURONIDE-LINKER DRUG CONJUGATES | UGT2B7, UGT1A1, UGT2B17 | LTB4R 1563/4885 |
| US-20250236594-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | LTB4R 2470/4885 |
| US-20250236674-A9 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | LTB4R 3875/4885 |
| US-20250002595-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | LTB4R 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.